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ABSTRACT
Objectives: The purpose of this study was to investigate dolutegravir (DTG) use among women and exposure to DTG dur-
ing pregnancy in real world in Central and Eastern Europe and neighboring countries. 
Material and methods: Centres from 20 countries included in the Euroguidelines in Central and Eastern Europe (ECEE) 
Network and Finland were asked to complete an on-line questionnaire. 
Results: Seven centres from Czech Republic, Finland, Greece, Poland, Slovakia, and Turkey provided detailed information. 
DTG exposure was reported in 415 women, of which 26 were during pregnancy. Of those, 22 were on DTG at the time of 
conception and 4 had started DTG during pregnancy. Few women had conventional risk factors. The data on folic acid us-
age was unknown for eight women; 14 were using and four were not using folic acid. Four pregnancies were ongoing at 
the time of the study and of those with an outcome, 77.3% resulted with term, 13.6% preterm delivery, 4.5% spontaneous 
and 4.5% medical abortion. 
Conclusions: The DTG signal report indicates the importance of safety research for drug use in pregnancy and highlights 
the urgent need for systematic surveillance of pregnancy outcomes and neonatal surveillance. Countries with low- or 
moderate HIV prevalence should be included in studies reviewing pregnancy outcomes and in any surveillance system to 
ensure the accuracy of drug safety revision.
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INTRODUCTION
Integrase strand transfer inhibitors (InSTIs) have become 
the mainstay of antiretroviral treatment (ART) recently ow-
ing to their high virologic activity, durability, minimized 
drug-drug interactions, low adverse event profile, and tol-
erability [1]. They are recommended as first-line antiretroviral 
drugs to be included in the treatment regimens of ART-naive 
patients in major guidelines [2, 3] and becoming more widely 
accessible across national guidelines in the Sentral and East-
ern European (CEE) region [4]. Dolutegravir (DTG) has been 
studied extensively among adults and children living with HIV 
and has replaced efavirenz (EFV) in the latest updated World 
Health Organization (WHO) guidelines [3]. However, the in-
terim analysis of the Tsepamo study comparing DTG with 
EFV revealed a higher rate of neural tube defects (NTDs) in 
infants born to mothers using DTG at conception compared 
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to those using EFV or non-DTG-containing regimens [5]. This 
unexpected finding resulted in safety warnings for the use 
of DTG in pregnant women and women of childbearing age, 
which restricted its use significantly [6]. It is estimated that 
restricting DTG use may compromise the overall benefit and 
access to modern combination ART for women living with HIV 
[7]. In order to balance the risks and benefits at the population 
level it is necessary to assess what the size of the population 
at risk is i.e. the number of women of childbearing age and 
the number of women conceiving on the drug.
Objectives
The aim of this study was therefore to investigate DTG 
use among women and exposure to DTG during pregnancy 
in real world in Central and Eastern Europe and neighbor-
ing countries where epidemiological data are few and HIV 
prevalence is low- or moderate-level.
MATERIAL AND METHODS
Centres from 20 countries included in the Euroguide-
lines in Central and Eastern Europe (ECEE) Network along 
with Finland were approached in June 2018 and were asked 
to complete an on-line questionnaire about DTG availability, 
the scale of its use among women, and exposure to DTG dur-
ing pregnancy (Tab. 1). DTG was available in twelve centres, 
and eight centres reported use of DTG in pregnant women. 
Seven centres from six countries (Czech Republic, Finland, 
Greece, Poland, Slovakia, and Turkey) provided detailed in-
formation on the use of DTG during pregnancy, and data on 
other risk factors. Follow-up was censored at 31stJuly, 2018. 
RESULTS
A total of 415 women were exposed to DTG in seven 
centres and 26 were exposed during pregnancy. Of those, 
22 were on DTG at the time of conception and 4 had started 
DTG during pregnancy. In only one patient who conceived 
a month before the warning for DTG use in pregnancy was 
released, the ART regimen was switched to darunavir/ritona-
vir + raltegravir (RAL). The remaining patients stayed on DTG.
Few women had conventional risk factors. Only one 
woman continued to use psychoactive substances and al-
cohol during pregnancy. Two women stopped psychoac-
tive drugs and one alcohol after they became pregnant. 
Four were smokers at the time of conception; two of those 
stopped after being pregnant.
The status of acute or reactive TORCH diseases was avail-
able for 23 women and for all it was negative. Hepatitis C 
antibodies were negative for 23 women, two had positive 
antibodies with confirmed HCV RNA positivity, and one had 
positive antibodies but an unknown RNA status.
Other concomitant illnesses included three hypothyreo-
sis, one autoimmune hepatitis, one insulin-dependent diabe-
tes, and one systemic lupus erythematosus. One woman had 
gestational diabetes stage A and one Rh incompatibility.
The data on folic acid usage was unknown for eight 
women, 14 were using and four were not using folic acid.
The median number of prior pregnancies was one [inter-
quartile range (IQR): 0–3]. Six had a prior caesarian section 
(CS), six were reported to have an induced abortion, and 
four a spontaneous abortion when HIV positive. 
Four pregnancies were ongoing at the time of the 
study. Of the 22 pregnancies with an outcome, there were 
17 (77.3%) term deliveries, three (13.6%) preterm deliveries, 
one (4.5%) spontaneous and one (4.5%) medical abortion.
DISCUSSION
This study is the first to report on DTG use among 
women and during pregnancy in ECEE Network countries 
showing that a substantial number of women were exposed 
to DTG in the region. The introduction of InSTIs to the mar-
ket in Central and Eastern Europe, especially in low and 
lower-middle income countries was delayed. In our study 
only 12 out of 20 centres had access to the drug, all of which 
are high-income or upper-middle income countries. There 
seems to be no improvement over time, as similarly in 
a study from 2015 including 24 countries from the Eastern 
and Central Europe, DTG was available in half, RAL in 70%, 
and elvitegravir fixed-dose combination only in 20% and 
again the majority (75%) was high or upper-middle income 
countries [8]. The relatively high number of women exposed 
to DTG in our study, is an indicator that DTG has become 
a preferable antiretroviral drug in the region.
Initially a few small cohorts from Europe and North 
America and a larger series from Botswana (the Tsepamo 
study) reported no evidence of increased birth defects in 
infants born to mothers who conceived while using DTG 
[9–13]. However, in April 2018, an unplanned interim analy-
sis requested by the WHO of the Tsepamo-cohort revealed 
an unexpectedly higher rate of NTDs among infants born 
to mothers who conceived on DTG compared to those us-
ing non-DTG regimens (0.94% and 0.12%, respectively) [5].
This unexpected finding resulted with a warning mes-
sage from the European Medicines Agency (EMA) and the 
WHO for designing ART regimens for women of reproduc-
tive age and pregnant women based on drugs with reliable 
efficacy and safety data such as an efavirenz–based regimen. 
[6, 14]. Similarly, all major guidelines issued new recom-
mendations regarding DTG use in women of childbearing 
age and in pregnant women [2].
In African countries the warnings on DTG resulted in al-
most immediate banning of the drug use among women of 
reproductive age [15]. Shutting off access to a superior regi-
men without extensive discussions with the relevant party 
was considered unacceptable and was widely criticized by 
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women’s organizations in Africa [15]. A modelling study to 
compare various scenarios of ART policy in a hypothetical 
southern African population showed that the benefits of 
DTG should not be sacrificed for the potential risk of NTDs 
in a woman who has not conceived yet [7]. Although the 
HIV epidemic in ECEE Network is concerning in terms of 
women, the implications of such an approach has not been 
discussed for this region. Most of the Central and Eastern 
European region has experienced a low- or moderate-level 
epidemic and thus has not received enough attention for 
many years [4, 16]. However, in many of those countries the 
epidemic is rapidly rising and mother-to-child transmission 
is still of concern [17]. DTG-based therapy proved to be effec-
tive in achieving rapid viral suppression in pregnant women, 
even in late presenters and those with highly resistant virus, 
and in preventing mother-to-child transmission. This makes 
it an attractive choice in many settings including pregnancy 
[12, 18–21]. DTG is becoming a preferred antiretroviral drug 
in the region and reliable data are required urgently for 
such settings. 
Table 1. Questionnaire used for data collection
Question Response choice Open ended question
Number of women on DTG in your centre: Number n/a
Number of women who got pregnant while being on DTG: Number n/a
Number of women who started DTG during pregnancy: Number n/a
Date of starting DTG: Date/Time
If DTG was switched provide date of stopping DTG: Date/Time
If DTG was switched provide name of new ARVs: Text Yes
NNRTI used in this pregnancy: Text Yes
Concurrent use of other medication (not ARV): Yes (please specify)/no/unknown Yes
Concurrent use of folic acid: Yes (please specify)/no/unknown Yes
Any health problems during pregnancy: Yes (please specify)/no/unknown Yes
HCV status: HCV antibodies negative No
  HCV antibodies positive
  HCV antibodies positive confirmed with HCV RNA
  HCV antibodies positive but HCV RNA not performed
Date of pregnancy start:  Date/Time n/a
Number of pregnancies: Number n/a
Outcome of past pregnancies (please describe): Text Yes
Outcome of pregnancy exposed to DTG: Term delivery Yes
  Preterm delivery (< 37 gestation week)
  Abortion
  Other (please describe)
Newborn outcome: Text Yes
Smoking: Yes and continued in pregnancy No
  Yes, but stopped at the begining of pregnancy
  No
Alcohol: Yes and continued in pregnancy No
  Yes, but stopped at the begining of pregnancy
  No
Psychoactive substance use: Yes and continued in pregnancy No
  Yes, but stopped at the begining of pregnancy
  No
TORCH diseases: Yes (please specify)/no/unknown Yes
Date of delivery: Date/Time n/a
If not yet delivered - date of expected delivery: Date/Time n/a
ARV — antiretroviral; DTG — dolutegravir; HCV — hepatitis C virus; NNRTI — non-nucleoside reverse transcriptase inhibitor; RNA — ribonucleic acid; TORCH 
— toxoplasma-other-rubella-cytomegalovirus-herpes
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In the general population NTDs were responsible for 
the highest disability and mortality rate among all birth 
defects. Although the etiology of NTDs is not clear yet sev-
eral factors such as genetics, nutrition, and environmental 
factors were suggested. Two randomized controlled studies 
and several observational studies showed that NTDs were 
prevented by 50% if women consumed a folic acid-contain-
ing supplement before and during early pregnancy [22, 23]. 
An important finding in our study was that almost half of the 
women who conceived on DTG were either not using folic 
acid or had no available data on its use, which seems like 
a significant gap in prevention of NTDs. In addition to folic 
acid depletion, obesity, poor control of diabetes mellitus, 
and use of some anti-epileptic drugs were also associated 
with a higher risk of spina bifida or anencephaly in the infant 
[24–28]. In our study concomitant illnesses reported among 
pregnant women exposed to DTG were three hypothyreosis, 
one autoimmune hepatitis, one insulin-dependent diabetes, 
and one systemic lupus erythematosus. One woman had 
gestational diabetes stage A and one Rh incompatibility. 
We would like therefore to highlight the importance of 
complete assessment of medical history in women exposed 
to antiviral drugs in pregnancy. Neglecting to collect and 
analyze these data may result in overestimating the toxicity 
related to antiretroviral drugs and undermining women’s 
rights to best possible standard of care [29]. The latest results 
of the Tsepamo study from Botswana suggest that although 
lower than the previous rate (0.67%), the increased risk still 
remains. On the other hand, these findings were not yet rep-
licated either by case series, observational cohorts or joined 
pregnancy surveillance reports [12, 30–33]. Therefore, the 
current scene is that the controversy has not resolved yet. 
The DTG story indicates the importance of safety re-
search for drug use in pregnancy. Moreover, it highlights 
the urgent need for systematic surveillance of pregnancy 
outcomes and neonatal surveillance. Mechanisms ensuring 
such reporting with necessary quality, e.g. excluding double 
reporting, are necessary to ascertain prolonged benefit 
from ART irrespective of gender [34]. Another subject of 
discussion was that in order to refute an NTD signal a large 
number of preconception exposures would be required. 
As estimated by Schomaker et al [35] if one new defect 
would be reported we would need 2000 exposures to see 
a lower confidence interval to overlap non-DTG prevalence. 
Therefore countries with low- or moderate HIV prevalence 
should be included in studies reviewing pregnancy out-
comes as well as in any surviellance system in order to 
ascertain the completeness of drug safety revision. 
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